Tigecycline is efficacious in the treatment of complicated intra-abdominal infections

International Journal of Surgery

Volumn 3, Issue 1, 2005, Pages 35-47

  Fomin, Peter ^a   Beuran, Mircea ^b   Gradauskas, Audrius ^c   Barauskas, Giedrius ^d   Datsenko, Alexey ^e   Dartois, Nathalie ^f   Ellis Grosse, Evelyn ^g   Loh, Evan ^g  

^a BOGOMOLETS NATIONAL MEDICAL UNIVERSITY   (Ukraine)

^b UNIVERSITY EMERGENCY HOSPITAL BUCHAREST   (Romania)

^c VILNIUS UNIVERSITY   (Lithuania)

^d KAUNAS UNIVERSITY OF MEDICINE HOSPITAL   (Lithuania)

^e City Clinical Multiple Discipline Hospital   (Ukraine)

^f Office 06TA024   (France)

^g PFIZER INC   (United States)

Author keywords

Complicated intra abdominal infections; Efficacy; Glycylcycline; Imipenem cilastatin; In vitro activity; Safety; Tigecycline

Indexed keywords

ANTIBIOTIC AGENT; ASPARTATE AMINOTRANSFERASE; CILASTATIN PLUS IMIPENEM; GLYCYLCYCLINE DERIVATIVE; LACTATE DEHYDROGENASE; TIGECYCLINE;

ABDOMINAL ABSCESS; ABDOMINAL INFECTION; ABDOMINAL PAIN; ABNORMAL HEALING; ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ABSCESS; ADULT; AGED; ANEMIA; APPENDICITIS; ASTHENIA; CARDIOVASCULAR DISEASE; CHOLECYSTITIS; CLINICAL TRIAL; COHORT ANALYSIS; CONFERENCE PAPER; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIGESTIVE SYSTEM DISEASE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FEVER; HEADACHE; HUMAN; HYPERTENSION; HYPOPROTEINEMIA; INFECTION; LYMPHATIC SYSTEM DISEASE; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MULTICENTER STUDY; NAUSEA; NUTRITIONAL DISORDER; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT OUTCOME; VOMITING;

EID: 23244467895     PISSN: 17439191     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijsu.2005.03.011     Document Type: Conference Paper

References (29)

1. J.S. Solomkin, J.E. Mazuski, and E.J. Baron Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections Clin Infect Dis 37 2003 997 1005
2. S.L. Gorbach Intra-abdominal infections [comment] Clin Infect Dis 17 1993 961 965
3. B. Lorber, and R.M. Swenson The bacteriology of intra-abdominal infections Surg Clin North Am 55 1975 1349 1354
4. M.E. de Vera, and R.L. Simmons Antibiotic-resistant enterococci and the changing face of surgical infections Arch Surg 131 1996 338 342
5. K. Krobot, D. Yin, Q. Zhang, S. Sen, A. Altendorf-Hofmann, and J. Scheele Effect of inappropriate initial empiric antibiotic therapy on outcome of patients with community-acquired intra-abdominal infections requiring surgery Eur J Clin Microbiol Infect Dis 23 2004 682 687
6. J. Valles, J. Rello, A. Ochagavia, J. Garnacho, and M.A. Alcala Community-acquired bloodstream infection in critically ill adult patients: impact of shock and inappropriate antibiotic therapy on survival Chest 123 2003 1615 1624
7. P.J. Petersen, N.V. Jacobus, W.J. Weiss, P.E. Sum, and R.T. Testa In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936) Antimicrob Agents Chemother 43 1999 738 744
8. A.C. Gales, and R.N. Jones Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1,203 recent clinical bacterial isolates Diagn Microbiol Infect Dis 36 2000 19 36
9. P.J. Petersen, P.A. Bradford, W.J. Weiss, T.M. Murphy, P.E. Sum, and S.J. Projan In vitro and in vivo activities of tigecycline (GAR-936), daptomycin, and comparative antimicrobial agents against glycopeptide-intermediate Staphylococcus aureus and other resistant gram-positive pathogens Antimicrob Agents Chemother 46 2002 2595 2601
10. D. Milatovic, F.J. Schmitz, J. Verhoef, and A.C. Fluit Activities of the glycylcycline tigecycline (GAR-936) against 1,924 recent European clinical bacterial isolates Antimicrob Agents Chemother 47 2003 400 404
11. R. Patel, M.S. Rouse, K.E. Piper, and J.M. Steckelberg In vitro activity of GAR-936 against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae Diagn Microbiol Infect Dis 38 2000 177 179
12. H.W. Boucher, C.B. Wennersten, and G.M. Eliopoulos In vitro activities of the glycylcycline GAR-936 against gram-positive bacteria Antimicrob Agents Chemother 44 2000 2225 2229
13. E. Cercenado, S. Cercenado, J.A. Gomez, and E. Bouza In vitro activity of tigecycline (GAR-936), a novel glycylcycline, against vancomycin-resistant enterococci and staphylococci with diminished susceptibility to glycopeptides J Antimicrob Chemother 52 2003 138 139
14. D.E. Low, B.N. Kreiswirth, K. Weiss, and B.M. Willey Activity of GAR-936 and other antimicrobial agents against North American isolates of Staphylococcus aureus Int J Antimicrob Agents 20 2002 220 222
15. D.J. Biedenbach, M.L. Beach, and R.N. Jones In vitro antimicrobial activity of GAR-936 tested against antibiotic-resistant gram-positive blood stream infection isolates and strains producing extended-spectrum beta-lactamases Diagn Microbiol Infect Dis 40 2001 173 177
16. T.G. Emori, and R.P. Gaynes An overview of nosocomial infections including the role of the microbiology laboratory Clin Microbiol Rev 6 1993 428 442
17. M.E. Falagas, L. Barefoot, J. Griffith, R. Ruthazar, and D.R. Snydman Risk factors leading to clinical failure in the treatment of intra-abdominal or skin/soft tissue infection Eur J Clin Microbiol Infect Dis 15 1996 913 921
18. J.E. Mazuski, R.G. Sawyer, A.B. Nathens, J.T. DiPiro, M. Schein, and K.A. Kudsk The Surgical Infection Society guidelines on antimicrobial therapy for intra-abdominal infections: an executive summary Surg Infect (Larchmt) 3 2002 161 173
19. L.A. Rocha, J.R. Azanza, J.L. Balibrea, M. Cainzos, J.A. Garcia-Rodriguez, and M. Gomis Guidelines for empirical antibiotic treatment of intra-abdominal infections. Spanish Society of Chemotherapy Rev Esp Quimioter 13 2000 65 72
20. G. Muralidharan, M. Micalizzi, J. Speth, D. Raible, and S. Troy Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects Antimicrob Agents Chemother 49 2005 220 229
21. G. Muralidharan, R.J. Fruncillo, M. Micalizzi, D.G. Raible, and S.M. Troy Effects of age and sex on single-dose pharmacokinetics of tigecycline in healthy subjects Antimicrob Agents Chemother 49 2005 1656 1659
22. Sesoko S, Umemura K, Nakashima M. Pharmacokinetics (PK), safety and tolerability of tigcycline (GAR-936) in healthy Japanese males. Presented at the 42nd Interscience Conference of Antimicrobial Agents and Chemotherapy. 2002;42:22.
23. Murray JA, Wilson S, Klein S, Yellin A, Loh E. The clinical response to tigecycline in the treatment of complicated intra-abdominal infections in hospitalized patients. A phase 2, clinical trial. Presented at the 43rd Interscience Conference of Antimicrobial Agents and Chemotherapy. 2003;43:416.
24. R.G. Postier, S.L. Green, S.R. Klein, E.J. Ellis-Grosse, E. Loh, and Tigecycline 200 Study Group Results of a multicenter, randomized, open-label efficacy and safety study of two doses of tigecycline for complicated skin and skin-structure infections in hospitalized patients Clin Ther 26 2004 704 714
25. Troy SM, Mauralidharan G, Micalizzi M, Mojavarian P, Salacinski L, Raible D. The effects of renal disease on the pharmacokinetics of tigecycline (GAR-936). Presented at the 43rd Interscience Conference of Antimicrobial Agents and Chemotherapy. Poster A-22; 2003.
26. A. Basoli, E.Z. Meli, P. Mazzocchi, and V. Speranza Imipenem/cilastatin (1.5 g daily) versus meropenem (3.0 g daily) in patients with intra-abdominal infections: results of a prospective, randomized, multicentre trial Scand J Infect Dis 29 1997 503 508
27. J. Solomkin, H. Reinhart, E. Dellinger, J.M. Bohnen, O.D. Rotstein, and S.B. Vogel Results of a randomized trial comparing sequential intravenous/oral treatment with ciprofloxacin plus metronidazole to imipenem/cilastatin for intra-abdominal infections Ann Surg 223 1996 303 315
28. B. Brismar, A. Malmborg, G. Tunevall, B. Wretlind, L. Bergman, and L.O. Mentzing Piperacillin-tazobactam versus imipenem-cilastatin for treatment of intra-abdominal infections Antimicrob Agents Chemother 36 1992 2766 2773
29. J.S. Solomkin, E.P. Dellinger, N.V. Christou, and R.W. Busuttil Results of a multicenter trial comparing imipenem/cilastatin to tobramycin/clindamycin for intra-abdominal infections Ann Surg 212 1990 581 591